Search Results

Aquestive Therapeutics, Inc. announced that the Aquestive management team will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism and host investor meetings on July 9, 2024.

Aquestive Therapeutics, Inc. today announced the appointment of Abigail Jenkins to the Company’s Board of Directors, effective April 1, 2024.

Aquestive Therapeutics, Inc. today announced it has strengthened its leadership team with three executive appointments ahead of the anticipated launch of Anaphylm™.

Aquestive Therapeutics, Inc. today announced the closing of its previously announced underwritten public offering of 16,666,667 shares of its common stock at the public offering price of $4.50 per share.

Aquestive Therapeutics, Inc. today released positive topline pharmacokinetic (PK) data from the temperature / pH study of its product candidate Anaphylm™ (epinephrine) Sublingual Film.

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, announced today that the management team will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13th.

Aquestive Therapeutics, Inc. today announced that it will report results for the first quarter ended March 31, 2024 and provide an update on recent developments in its business after market close on Tuesday, May 7, 2024.